Accretion Nutraveda Reports Strong FY26 Results Amid Board Changes

Accretion Nutraveda Limited announced robust financial results for the fiscal year ending March 31, 2026, with revenue surging 110% to ₹33.60 crore and profit after tax doubling to ₹5.07 crore. The company's board also saw significant shifts with the departure of two independent directors and the appointment of two new members.

Key Announcements and Financial Performance

The company filed its audited financial results for FY26 on May 8, 2026, receiving an unmodified opinion from its statutory auditors. Revenue from operations reached ₹33.60 crore, marking a 110% increase from ₹16.00 crore in FY25. Profit After Tax (PAT) nearly doubled to ₹5.07 crore, up from ₹2.50 crore in the prior fiscal year.

Board of Directors Updates

Accretion Nutraveda disclosed significant board-level adjustments. Two Independent Directors, Mr. Arun Dash and Mr. Mahipal Singh Chouhan, resigned. Following these resignations, Mr. Chand Rameshbhai Kanabar and Ms. Grishma A Shewale were appointed as additional Non-Executive Independent Directors. Their appointments are intended for a five-year term, pending shareholder approval.

Audit Partner Appointments

For the upcoming fiscal year 2026-27, the company re-appointed M/s. Sakhiya & Co. as its Secretarial Auditors. M/s. UMT & Co. were appointed as Internal Auditors.

IPO Fund Utilization

Accretion Nutraveda, which manufactures nutraceutical products and dietary supplements, raised ₹24.77 crore through its Initial Public Offering (IPO) in September 2023. These funds were designated for working capital and general corporate purposes. As of March 31, 2026, the company had utilized ₹18.21 crore of the IPO proceeds, leaving a balance of ₹6.55 crore.

Performance Drivers and Governance

The strong financial performance suggests significant market traction and operational efficiency for Accretion Nutraveda in FY26. The doubling of revenue and profit highlights effective sales strategies and potential market share growth. However, the resignation of two independent directors signals a transition in the board's composition. While new directors can bring fresh perspectives, this shift may lead to initial questions about board stability and independence until new members are fully integrated.

Market Context

Accretion Nutraveda operates within the growing nutraceutical and health supplements market. For broader context, Eris Lifesciences, a company focused on branded health products and nutrition, reported approximately ₹2,368 crore in revenue and ₹380 crore in PAT for FY26, indicating a larger scale in the overall health segment.

Key Risks and Investor Focus

Investors will closely monitor shareholder voting on the appointment of the new independent directors. The deployment strategy and timeline for the remaining ₹6.55 crore in IPO funds are also key areas of interest. Any further strategic initiatives from the new board composition will be watched closely. Management commentary on sustained growth drivers for FY27 during upcoming calls will be important.